MCID: PRS116
MIFTS: 39

Prostate Cancer 1

Categories: Genetic diseases, Cancer diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Prostate Cancer 1

MalaCards integrated aliases for Prostate Cancer 1:

Name: Prostate Cancer 1 54 13
Prostate Cancer, Hereditary, 1 71 29 52
Familial Prostate Cancer 1 71
Prostate Cancer, Familial 69
Prca1 71
Hpc1 71

Characteristics:

OMIM:

54
Inheritance:
autosomal dominant form


HPO:

32
prostate cancer 1:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

OMIM 54 601518
MedGen 40 C2931456
MeSH 42 D011471

Summaries for Prostate Cancer 1

UniProtKB/Swiss-Prot : 71 Prostate cancer, hereditary, 1: A condition associated with familial predisposition to cancer of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma.

MalaCards based summary : Prostate Cancer 1, also known as prostate cancer, hereditary, 1, is related to prostate cancer and prostatitis, and has symptoms including prostate cancer and neoplasm. An important gene associated with Prostate Cancer 1 is RNASEL (Ribonuclease L), and among its related pathways/superpathways is Hepatitis C. The drugs Goserelin and Metformin have been mentioned in the context of this disorder. Affiliated tissues include prostate, bone and lung.

Description from OMIM: 601518

Related Diseases for Prostate Cancer 1

Graphical network of the top 20 diseases related to Prostate Cancer 1:



Diseases related to Prostate Cancer 1

Symptoms & Phenotypes for Prostate Cancer 1

Symptoms via clinical synopsis from OMIM:

54

Oncology:
prostate cancer


Clinical features from OMIM:

601518

Human phenotypes related to Prostate Cancer 1:

32
id Description HPO Frequency HPO Source Accession
1 prostate cancer 32 HP:0012125
2 neoplasm 32 HP:0002664

Drugs & Therapeutics for Prostate Cancer 1

Drugs for Prostate Cancer 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 699)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Goserelin Approved Phase 4,Phase 3,Phase 2,Phase 1 65807-02-5 47725 5311128
2
Metformin Approved Phase 4,Phase 3,Phase 2,Phase 1 657-24-9 14219 4091
3
Dopamine Approved Phase 4,Phase 1,Phase 2 51-61-6, 62-31-7 681
4
Histamine Approved, Investigational Phase 4,Phase 2 75614-87-8, 51-45-6 774
5
Lenograstim Approved Phase 4,Phase 2,Phase 3,Phase 1 135968-09-1
6
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 83-43-2 6741
7
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 50-24-8 5755
8
Ropivacaine Approved Phase 4,Phase 3 84057-95-4 71273 175805
9
Leuprolide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 53714-56-0 3911 657181
10
Methyltestosterone Approved Phase 4,Phase 3,Phase 2,Phase 1 58-18-4 6010
11
Testosterone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 58-22-0 6013
12
Bicalutamide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 90357-06-5 56069 2375
13
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 53-03-2 5865
14
Zoledronic acid Approved Phase 4,Phase 3,Phase 2,Phase 1 118072-93-8 68740
15
Acetaminophen Approved Phase 4,Phase 2,Phase 1 103-90-2 1983
16
Celecoxib Approved, Investigational Phase 4,Phase 2,Phase 1 169590-42-5 2662
17
Flutamide Approved Phase 4,Phase 3,Phase 2,Phase 1 13311-84-7 3397
18
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 50-02-2 5743
19
Diphenhydramine Approved Phase 4,Phase 2,Phase 1 58-73-1, 147-24-0 3100
20
Granisetron Approved, Investigational Phase 4 109889-09-0 3510
21
Metoclopramide Approved, Investigational Phase 4 364-62-5 4168
22
Ondansetron Approved Phase 4 99614-02-5 4595
23
Promethazine Approved Phase 4,Phase 2,Phase 1 60-87-7 4927
24
Ranitidine Approved Phase 4,Phase 2 66357-59-3, 66357-35-5 3001055
25
Dutasteride Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 164656-23-9 152945 6918296
26
Benzocaine Approved Phase 4,Phase 3,Phase 1,Phase 2 1994-09-7, 94-09-7 2337
27
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
28
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
29
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
30
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
31
Desflurane Approved Phase 4 57041-67-5 42113
32
Nitric Oxide Approved Phase 4,Phase 2 10102-43-9 145068
33
Ciprofloxacin Approved, Investigational Phase 4 85721-33-1 2764
34
Tadalafil Approved, Investigational Phase 4,Phase 3 171596-29-5 110635
35
Gabapentin Approved, Investigational Phase 4,Phase 3 60142-96-3 3446
36
Hydromorphone Approved, Illicit Phase 4 466-99-9 5284570
37
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
38
Denosumab Approved Phase 4,Phase 3,Phase 2,Phase 1 615258-40-7
39
Menthol Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 2216-51-5 16666
40
Midazolam Approved, Illicit Phase 4,Phase 1 59467-70-8 4192
41
Pamidronate Approved Phase 4 40391-99-9 4674
42
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
43
Mepivacaine Approved, Vet_approved Phase 4 96-88-8 4062
44 tannic acid Approved, Nutraceutical Phase 4,Phase 3,Phase 1,Phase 2
45
B-Carotene Approved, Nutraceutical Phase 4 7235-40-7 5280489
46
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4,Phase 2 11103-57-4, 68-26-8 445354
47
Iodine Investigational Phase 4,Phase 3,Phase 2,Phase 1 7553-56-2 807
48
Docetaxel Approved May 1996, Investigational Phase 4,Phase 3,Phase 2,Phase 1 114977-28-5 148124 9877265
49 Dexchlorpheniramine Experimental Phase 4,Phase 2 25523-97-1
50
gamma-Aminobutyric acid Investigational Phase 4,Phase 3 56-12-2 119

Interventional clinical trials:

(show top 50) (show all 1999)

id Name Status NCT ID Phase Drugs
1 FINNPROSTATE Study VII: Intermittent Versus Continuous Androgen Deprivation in Patients With Advanced Prostate Cancer Unknown status NCT00293670 Phase 4 Goserelin (Zoladex)
2 Treatment of Localized Prostate Cancer With High Intensity Focused Ultrasound Using the Sonablate® 500 System in Canada Unknown status NCT00573586 Phase 4
3 Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy Unknown status NCT01379742 Phase 4
4 MR-Lymphography and Lymph Node Staging in Prostate Cancer Unknown status NCT00185029 Phase 4
5 Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer Unknown status NCT00906269 Phase 4 Sildenafil therapy plus post-NSRRP HBO2T;Sildenafil therapy plus sham post-NSRRP HBO2T
6 Metformin And Longevity Unknown status NCT02511665 Phase 4 Metformin;Placebo
7 Early Detection of Prostate Cancer by FACS Unknown status NCT00524823 Phase 4
8 Combination of Cabazitaxel With Prednisolone With Primary Prophylaxis With PEG-G-CSF in Treatment of Patients With Prostate Cancer Completed NCT02441894 Phase 4 CABAZITAXEL XRP6258;PEG-G-CSF;Prednisolone;Dexchlorpheniramine or Diphenhydramine;Ranitidine;Metoclopramide, Granisetron, or Ondansetron;Dexamethasone
9 Assessment Of Dutasteride (AVODART) In Extending The Time To Progression Of Low-Risk, Localized Prostate Cancer In Men Completed NCT00363311 Phase 4 Dutasteride;Matching placebo
10 Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer Completed NCT00199485 Phase 4 Angelica Sinensis
11 The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function Completed NCT01547416 Phase 4 epidural 250mL of 0.2% ropivacaine and 2 μg/mL of fentanyl, 5 mL/hr continuous infusion and 0.5 mL bolus dose;no epidural drug administered
12 The Effect of Propofol Based Total Intravenous Anesthesia on Oxidative Stress and Nitric Oxide Completed NCT02149628 Phase 4 propofol;Desflurane
13 Evaluate Recovery of Testosterone for Patients Using Eligard Completed NCT01136226 Phase 4 Eligard (TM)
14 Prostate Cancer Study In Men Who Have Failed First-Line Androgen Deprivation Therapy Completed NCT00470834 Phase 4 dutasteride;placebo;bicalutamide
15 Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer Completed NCT01649635 Phase 4 CABAZITAXEL (XRP6258);Prednisone;Ciprofloxacin;G-CSF (Granulocyte colony-stimulating factor)
16 A Study of Tadalafil After Radical Prostatectomy Completed NCT01026818 Phase 4 Tadalafil;Placebo
17 Local Anesthesia for Prostate Biopsy Completed NCT00422708 Phase 4
18 Global Performance Evaluation of the AMS CONTINUUM™ Device Completed NCT01083199 Phase 4
19 Benign Prostatic Hyperplasia (BPH) Screening Tool Case Finding Study in Subjects >=50 Years Completed NCT02757963 Phase 4
20 Effect of TachoSil® on Incidence of Symptomatic and Radiographic Lymphoceles After Extended Pelvic Lymph Node Dissection in Prostate and Bladder Cancer. Completed NCT02001857 Phase 4 1 TachoSil hemostatic sponge (9,5 cm x 4,8 cm) placed on each side on the external iliac artery.
21 Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer Completed NCT00391690 Phase 4 Zoledronic acid
22 Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy? Completed NCT00982800 Phase 4 Gabapentin;Placebo Sugar Pill
23 Hydroxyethyl Starch and Renal Function After Radical Prostatectomy Completed NCT01486563 Phase 4 Voluven (Hydroxyethyl starch 130/0,4);Sodium Chloride 9 mg/ml
24 Carotene and Retinol Efficacy Trial Completed NCT00712647 Phase 4 Beta Carotene and Retinol
25 Study on Enzalutamide and Flutamide in Patients With Castration Resistant Prostate Cancer Recruiting NCT02918968 Phase 4 Enzalutamide;Flutamide
26 Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer Recruiting NCT01581749 Phase 4
27 4-weekly Versus 12-weekly Administration of Bone-targeted Agents in Patients With Bone Metastases Recruiting NCT02721433 Phase 4 Pamidronate;Denosumab;Zoledronate
28 Phase IV Study to Evaluate Bone Mineral Density in No-bone Metastatic Prostate Cancer Treated With Degarelix Recruiting NCT03202381 Phase 4 Degarelix
29 Cabazitaxel Versus the Switch to Alternative AR-targeted Agent (Enzalutamide or Abiraterone) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Previously Treated With Docetaxel and Who Rapidly Failed a Prior AR-targeted Agent Recruiting NCT02485691 Phase 4 cabazitaxel XRP6258;enzalutamide;abiraterone acetate;prednisone
30 Clinical Trial to Examine Individual Pain Tolerance in the Use of Two Anesthetic Techniques to Perform Saturation Prostate Biopsy Recruiting NCT02909049 Phase 4 MIDAZOLAM;MEPIVACAÍNE;FENTANILE;KETAMINE
31 Endothelial Function in Prostate Cancer Patients on Degarelix vs. Luteinizing Hormone-Releasing Hormone Agonists Active, not recruiting NCT02475057 Phase 4 Degarelix (LHRH antagonist);LHRH agonist
32 Dissemination of Prostate Cancer Screening to PCP's in African American Communities Terminated NCT00629330 Phase 4
33 Assessment and Tracking of Long-term Alefacept Safety Terminated NCT00454701 Phase 4 Alefacept exposure
34 Firmagon (Degarelix) Intermittent Therapy Terminated NCT01512472 Phase 4 degarelix
35 GP Extended Action Triptorelin Terminated NCT01673984 Phase 4 Decapeptyl® SR 22.5mg;Decapeptyl® SR 11.25mg; Prostap® 3 DCS 11.25mg; Zoladex® LA 10.8mg
36 A Study of Enzalutamide Re-treatment in Metastatic Castration-resistant Prostate Cancer After Docetaxel and/or Cabazitaxel Treatment Terminated NCT02441517 Phase 4 Enzalutamide
37 Community Interventions in Non-Medical Settings to Increase Informed Decision Making for Prostate Cancer Screening Unknown status NCT00207636 Phase 3
38 Prostate Cancer Survivors Moving Toward Exercise (PROMOTE) Trial Unknown status NCT01410656 Phase 3
39 Long Acting LHRH Versus Short Acting LHRH in the Treatment of Prostate Cancer Unknown status NCT00175383 Phase 3 luteinizing hormone-releasing hormone (LHRH) short acting or long acting
40 GTN Therapy on Biomarkers of Immune Escape in Men With Biochemical Recurrence of Prostate Cancer After Primary Therapy Unknown status NCT01704274 Phase 3
41 Multicentric Study Comparing Carcinological and Functional Results of Surgery Unknown status NCT00502723 Phase 3
42 I-125 Versus Pd-103 for Low Risk Prostate Cancer Unknown status NCT00494039 Phase 3
43 Androgen Suppression Combined With Elective Nodal and Dose Escalated Radiation Therapy Unknown status NCT00175396 Phase 3
44 I-125 Versus Pd-103 for Medium Risk Prostate Cancer Unknown status NCT00486499 Phase 3
45 Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer Unknown status NCT00365105 Phase 3 zoledronic acid;Sm-153
46 A Prospective Randomized Phase III Study Comparing Hormonal Therapy +/-Docetaxel Unknown status NCT00764166 Phase 3 Docetaxel + hormonal treatment (LH-RH agonist);Hormonal treatment (LH-RH agonist)
47 Androgen Ablation With or Without Docetaxel in Treating Patients With Advanced Prostate Cancer Unknown status NCT00796458 Phase 3 docetaxel;releasing hormone agonist therapy
48 PR.7 Companion Trial: Effect of Intermittent Versus Continuous Androgen Suppression on Bone Loss and Body Composition Unknown status NCT00228124 Phase 3
49 Prostate Cancer, Androgen Deprivation Withdrawal and Intermittent Chemotherapy Unknown status NCT01224405 Phase 3 Docetaxel + LH-RH analogues;Docetaxel;Docetaxel;Continuous Docetaxel;Continuous Docetaxel
50 Active Surveillance, Radical Prostatectomy, or Radiation Therapy in Treating Patients With Localized Prostate Cancer Unknown status NCT00632983 Phase 3 cyproterone acetate;releasing hormone agonist therapy

Search NIH Clinical Center for Prostate Cancer 1

Genetic Tests for Prostate Cancer 1

Genetic tests related to Prostate Cancer 1:

id Genetic test Affiliating Genes
1 Prostate Cancer, Hereditary, 1 29

Anatomical Context for Prostate Cancer 1

MalaCards organs/tissues related to Prostate Cancer 1:

39
Prostate, Bone, Lung, Lymph Node, T Cells, Breast, Testes

Publications for Prostate Cancer 1

Articles related to Prostate Cancer 1:

id Title Authors Year
1
Long-term Efficacy and Safety of Enzalutamide Monotherapy in Hormone-naA^ve Prostate Cancer: 1- and 2-Year Open-label Follow-up Results. ( 25687533 )
2015
2
Management of locally advanced prostate cancer. 1. Staging, natural history, and results of radical surgery. ( 10926084 )
2000
3
A 6-Mb high-resolution physical and transcription map encompassing the hereditary prostate cancer 1 (HPC1) region. ( 10708513 )
2000
4
Prostate cancer: 1. The descriptive epidemiology in Canada. ( 9757178 )
1998
5
Characteristics of prostate cancer in families potentially linked to the hereditary prostate cancer 1 (HPC1) locus. ( 9333266 )
1997
6
A 72-year-old man with localized prostate cancer, 1 year later. ( 8627972 )
1996
7
Update on urology--prostate cancer. 1--The molecular basis for prostatic cancer: how it may influence treatment choice. ( 7781804 )
1995
8
Steroid-growth factor interaction in human prostate cancer. 1. Short-term effects of transforming growth factors on growth of human prostate cancer cells. ( 7974525 )
1994

Variations for Prostate Cancer 1

ClinVar genetic disease variations for Prostate Cancer 1:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 RNASEL NM_021133.3(RNASEL): c.793G> T (p.Glu265Ter) single nucleotide variant Pathogenic rs74315364 GRCh37 Chromosome 1, 182555149: 182555149
2 RNASEL NM_021133.3(RNASEL): c.3G> A (p.Met1Ile) single nucleotide variant Pathogenic rs74315365 GRCh37 Chromosome 1, 182555939: 182555939

Cosmic variations for Prostate Cancer 1:

9 (show top 50) (show all 217)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM1675924 WT1 prostate,NS,carcinoma,adenocarcinoma c.790C>G p.Q264E 7
2 COSM6005603 TSC2 prostate,NS,carcinoma,adenocarcinoma c.472G>A p.E158K 7
3 COSM6005601 TSC2 prostate,NS,carcinoma,adenocarcinoma c.392C>A p.P131H 7
4 COSM3212813 TSC1 prostate,NS,carcinoma,adenocarcinoma c.3100G>T p.G1034C 7
5 COSM3212858 TSC1 prostate,NS,carcinoma,adenocarcinoma c.439G>T p.G147W 7
6 COSM10662 TP53 prostate,NS,carcinoma,adenocarcinoma c.743G>A p.R248Q 7
7 COSM45103 TP53 prostate,NS,carcinoma,adenocarcinoma c.492G>A p.K164K 7
8 COSM13165 TP53 prostate,NS,carcinoma,adenocarcinoma c.800G>T p.R267L 7
9 COSM43906 TP53 prostate,NS,carcinoma,adenocarcinoma c.843C>A p.D281E 7
10 COSM43592 TP53 prostate,NS,carcinoma,adenocarcinoma c.395A>T p.K132M 7
11 COSM44135 TP53 prostate,NS,carcinoma,adenocarcinoma c.724T>G p.C242G 7
12 COSM11224 TP53 prostate,NS,carcinoma,adenocarcinoma c.394A>C p.K132Q 7
13 COSM43665 TP53 prostate,NS,carcinoma,adenocarcinoma c.746G>C p.R249T 7
14 COSM45032 TP53 prostate,NS,carcinoma,adenocarcinoma c.710T>G p.M237R 7
15 COSM44823 TP53 prostate,NS,carcinoma,adenocarcinoma c.981T>G p.Y327* 7
16 COSM45620 TP53 prostate,NS,carcinoma,adenocarcinoma c.704A>C p.N235T 7
17 COSM44431 TP53 prostate,NS,carcinoma,adenocarcinoma c.505A>G p.M169V 7
18 COSM12193 TP53 prostate,NS,carcinoma,adenocarcinoma c.668C>T p.P223L 7
19 COSM10828 TP53 prostate,NS,carcinoma,adenocarcinoma c.785G>A p.G262D 7
20 COSM10659 TP53 prostate,NS,carcinoma,adenocarcinoma c.817C>T p.R273C 7
21 COSM10656 TP53 prostate,NS,carcinoma,adenocarcinoma c.742C>T p.R248W 7
22 COSM11524 TP53 prostate,NS,carcinoma,adenocarcinoma c.730G>T p.G244C 7
23 COSM45623 TP53 prostate,NS,carcinoma,adenocarcinoma c.703A>C p.N235H 7
24 COSM44126 TP53 prostate,NS,carcinoma,adenocarcinoma c.507G>A p.M169I 7
25 COSM44137 TP53 prostate,NS,carcinoma,adenocarcinoma c.434T>A p.L145Q 7
26 COSM10646 TP53 prostate,NS,carcinoma,adenocarcinoma c.725G>A p.C242Y 7
27 COSM10724 TP53 prostate,NS,carcinoma,adenocarcinoma c.839G>C p.R280T 7
28 COSM44388 TP53 prostate,NS,carcinoma,adenocarcinoma c.853G>T p.E285* 7
29 COSM10731 TP53 prostate,NS,carcinoma,adenocarcinoma c.707A>G p.Y236C 7
30 COSM6932 TP53 prostate,NS,carcinoma,adenocarcinoma c.733G>A p.G245S 7
31 COSM45870 TP53 prostate,NS,carcinoma,adenocarcinoma c.715A>T p.N239Y 7
32 COSM45622 TP53 prostate,NS,carcinoma,adenocarcinoma c.461G>A p.G154D 7
33 COSM43956 TP53 prostate,NS,carcinoma,adenocarcinoma c.700T>A p.Y234N 7
34 COSM44299 TP53 prostate,NS,carcinoma,adenocarcinoma c.501G>A p.Q167Q 7
35 COSM10704 TP53 prostate,NS,carcinoma,adenocarcinoma c.844C>T p.R282W 7
36 COSM44996 TP53 prostate,NS,carcinoma,adenocarcinoma c.515T>C p.V172A 7
37 COSM10905 TP53 prostate,NS,carcinoma,adenocarcinoma c.451C>T p.P151S 7
38 COSM11287 TP53 prostate,NS,carcinoma,adenocarcinoma c.839G>T p.R280I 7
39 COSM10738 TP53 prostate,NS,carcinoma,adenocarcinoma c.542G>A p.R181H 7
40 COSM10672 TP53 prostate,NS,carcinoma,adenocarcinoma c.577C>T p.H193Y 7
41 COSM10808 TP53 prostate,NS,carcinoma,adenocarcinoma c.488A>G p.Y163C 7
42 COSM5708976 TET2 prostate,NS,carcinoma,adenocarcinoma c.5669A>G p.N1890S 7
43 COSM5413594 SUFU prostate,NS,carcinoma,adenocarcinoma c.50C>T p.A17V 7
44 COSM6005723 STAT5B prostate,NS,carcinoma,adenocarcinoma c.1529C>T p.A510V 7
45 COSM6005724 STAT5B prostate,NS,carcinoma,adenocarcinoma c.1025T>C p.L342P 7
46 COSM6005721 SRC prostate,NS,carcinoma,adenocarcinoma c.1116+4A>T p.? 7
47 COSM95272 SPOP prostate,NS,carcinoma,adenocarcinoma c.399C>G p.F133L 7
48 COSM220066 SPOP prostate,NS,carcinoma,adenocarcinoma c.305T>G p.F102C 7
49 COSM241746 SPOP prostate,NS,carcinoma,adenocarcinoma c.260A>C p.Y87S 7
50 COSM2769699 SMO prostate,NS,carcinoma,adenocarcinoma c.817T>C p.C273R 7

Expression for Prostate Cancer 1

Search GEO for disease gene expression data for Prostate Cancer 1.

Pathways for Prostate Cancer 1

Pathways related to Prostate Cancer 1 according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 10.74 EGFR RNASEL

GO Terms for Prostate Cancer 1

Sources for Prostate Cancer 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....